C

CRISPR Therapeutics AG (CRSP)

NGM – Real vaqt narxi. Valyuta: USD

52.83

-1.18 (-2.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

C

CRISPR Therapeutics AG (CRSP)

NGM – Real vaqt narxi. Valyuta: USD

52.83

-1.18 (-2.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

08.05.2026

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

08.05.2026

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

06.05.2026

Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case

Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 patients have initiated treatment, supporting a multibillion-dollar opportunity with a large, underpenetrated addressable market. CRSP's pipeline offers near-term catalysts in autoimmune and in-vivo gene editing, with several Phase 1 updates expected later this year.

06.05.2026

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.

05.05.2026

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

05.05.2026

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.

Videolar

09.04.2026

Neutral

Wall Street Is Completely Wrong About These 5 Stocks

15.07.2025

Neutral

The Big 3: ASML, GOOGL, CRSP

Press-relizlar

04.05.2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

11.03.2026

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50 million aggregate principal amount of the notes.

10.03.2026

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of the notes.

12.02.2026

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D.

Search stocks

CRISPR Therapeutics AG (CRSP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

Videolar

Press-relizlar

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results